Meeting
2019 ASCO Annual Meeting
Pembrolizumab (pembro) for recurrent head and neck squamous cell carcinoma (HNSCC): Post hoc analyses of phase 3 KEYNOTE-040 prior radiation treatment (RT) and disease state.
Authors
Kevin J. Harrington
The Institute of Cancer Research/The Royal Marsden NHS Foundation Trust National Institute of Health Research Biomedical Research Centre, London, United Kingdom
Kevin J. Harrington , Ezra E.W. Cohen , Denis Soulieres , José Dinis , Lisa F. Licitra , Myung-Ju Ahn , Ainara Soria , Jean-Pascal H. Machiels , Nicolas Mach , Ranee Mehra , Barbara Burtness , Jianxin Lin , Jonathan D. Cheng , Ramona F. Swaby , Christophe Le Tourneau
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT02252042
Citation
J Clin Oncol 37, 2019 (suppl; abstr 6026)
DOI
10.1200/JCO.2019.37.15_suppl.6026
Abstract #
6026
Poster Bd #
15
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Health-related quality of life (HRQoL) of pembrolizumab (pembro) vs standard of care (SOC) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in KEYNOTE-040.
First Author: Ezra E.W. Cohen
Poster
2023 ASCO Annual Meeting
Oral NRC-2694-A in combination with paclitaxel as therapy for recurrent and/or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) that progressed on or after an immune checkpoint inhibitor (ICI): A multi-center, single-arm, phase 2 trial.
First Author: Douglas Adkins
Poster
2019 ASCO Annual Meeting
EAGLE: A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
First Author: Lisa F. Licitra
Poster
2019 ASCO Annual Meeting
A global phase III multicenter, randomized, double-arm, open label trial of ASP-1929 photoimmunotherapy versus physician’s choice standard of care for the treatment of patients with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC).
First Author: Merrill A. Biel